SCHEDULE: Biotech Funds Adjust TScan Therapeutics Stake

Several Biotechnology Value Funds and associated entities have updated their beneficial ownership filings for TScan Therapeutics, Inc., reporting their holdings as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, reporting changes in beneficial ownership of TScan Therapeutics, Inc. common stock.
• The reporting persons include various Biotechnology Value Funds (BVF, BVF2, Trading Fund OS), their general partners (BVF GP, BVF2 GP, Partners OS), holding companies (BVF GPH, BVF Inc.), and Mark N. Lampert.
• As of June 30, 2026, the aggregate beneficial ownership reported by Mark N. Lampert and associated entities is approximately 9.99% of the outstanding shares.
• The filing details holdings of Pre-Funded Warrants and the limitations imposed by a 'Pre-Funded Warrants Blocker' which caps exercise to prevent exceeding 9.99% beneficial ownership.
• Specific holdings are detailed for BVF (5.7%), BVF2 (4.2%), and Trading Fund OS (less than 1%).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports on existing beneficial ownership stakes and does not contain new strategic information or financial performance updates.

Positives

• The filing clarifies the beneficial ownership stakes of several investment entities in TScan Therapeutics, Inc.
• The reporting persons are adhering to beneficial ownership limits, with a stated intention not to influence or change control of the issuer.

Negatives

• The filing does not contain any new financial results, strategic initiatives, or operational updates for TScan Therapeutics, Inc.
• The 'Pre-Funded Warrants Blocker' indicates a potential constraint on the full exercise of warrants, limiting immediate ownership increases.

Risks

• The 'Pre-Funded Warrants Blocker' limits the ability of reporting persons to exercise all their warrants, capping beneficial ownership at 9.99%.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding TScan Therapeutics, Inc.'s future performance. It solely reports on current beneficial ownership as of June 30, 2026.

Management Comments

• Each Reporting Person disclaims beneficial ownership of securities beneficially owned by other Reporting Persons, except as specified.
• The filing certifies that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in biotechnology companies. The focus on warrants and ownership caps is typical in this sector, reflecting strategic investment approaches and regulatory compliance.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership stakes, which can influence market perception and trading activity.
• Management: The reporting entities' stated intention not to influence control suggests a passive investment approach, which may be viewed positively by management.

Next Steps

• Continued monitoring of TScan Therapeutics, Inc. for future SEC filings and corporate developments.
• Potential future adjustments to beneficial ownership by the reporting entities.

Key Dates

Keywords

TScan Therapeutics, Schedule 13G, Beneficial Ownership, Pre-Funded Warrants, Biotechnology Value Fund, Investment Holdings, SEC Filing